Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Leisha A EmensLuciana MolineroSherene LoiHope S RugoAndreas SchneeweissVéronique DiérasHiroji IwataCarlos H BarriosMarina NechaevaAnh Nguyen-DucStephen Y ChuiAmreen HusainEric P WinerSylvia AdamsPeter SchmidPublished in: Journal of the National Cancer Institute (2022)
Although A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+.